By submitting this form, you are agreeing to the Terms of Use and Privacy Policy.
Coming Soon
The drug promethazine hydrochloride is a member of the phenothiazines drug class. Its primary function is that of an antihistamine, which means that it relieves allergy-related symptoms like itchiness, sneezing, and runny nose. It also has sedative qualities and is occasionally employed to relieve nausea and vomiting.The way that promethazine functions is by blocking the effects of histamine, a chemical that the body naturally produces.
The way that promethazine hydrochloride works is by inhibiting the effects of histamine, a substance that the body releases in response to allergens and is responsible for symptoms like swelling and itching. Promethazine hydrochloride can help lessen or get rid of these symptoms by inhibiting histamine.
It is often consumed orally and is available in a number of forms, including pills, capsules, suppositories, and syrups. To treat itching, it can also be injected or applied topically.
Promethazine hydrochloride can make you drowsy and make it difficult for you to do duties that call for attentiveness, such driving or operating machinery. As a result, it is advised that you refrain from doing so while taking this drug. Promethazine hydrochloride should also not be administered to children under the age of two since it may seriously impair their ability to breathe.
Global Promethazine Hydrochloride market accounted for $XX Billion in 2022 and is anticipated to reach $XX Billion by 2030, registering a CAGR of XX% from 2023 to 2030.
Promethazine Hydrochloride and Phenylephrine Hydrochloride Syrup (Promethazine/Phenylephrine) and Promethazine Hydrochloride, Phenylephrine are two more promethazine syrup formulations that Akorn, Inc. has released.
The existing Promethazine formulations from Akorn, such as Promethazine HCl Oral Solution, USP, Promethazine HCl and Codeine Phosphate Syrup CV, and Promethazine HCl and Dextromethorphan HCl Oral Solution, are supplemented by these two new products.
The U.S. Food and Drug Administration (FDA) gave its final approval to Mylan Pharmaceuticals Inc.’s Abbreviated New Drug Application (ANDA) for Promethazine Hydrochloride (HCl) Tablets, USP, 12.5 mg, 25 mg, and 50 mg. The symptoms of some allergic reactions, such as perennial and seasonal allergic rhinitis, are treated with promethazine HCl tablets.
